Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
A legfontosabb adatok
- Ki végzi
- Dompé Farmaceutici S.p.A
- Hol
- Atlanta, Augusta, Beaumont, Boston, Brooklyn, Charlottesville, Chicago, Clearwater, Columbia, Denison, Denver, Durham, Gary, Jacksonville, Knoxville, Midland, New York, Newton, Orange, Philadelphia, Portland, Richmond, Royal Oak, Salt Lake City, St Louis, Tucson és Washington D.C. (Egyesült Államok)Mind a 28 helyszín megnézéseMég 6 másik országban, 46 helyszínen
- Azonosító
- Állapot
- Leállítva
- Fázis
- 3. fázis
- Résztvevők
- 414 fő vett részt
- Kezdés
- 2022. ápr. 27.
- Befejezés
- 2024. szept. 27.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Reparixin
- Placebo
- A regiszteradat frissítve
- 2026. február 24.
- Miért állt le
- The study was stopped due to futility as per protocol
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Informed consent signed
- Male and female ≥18 years old
- Patients hospitalized for clinically suspected CAP, defined as the occurrence of (within 48h from hospital admission):; at least 1 of the following signs/symptoms: dyspnea, cough, purulent sputum, crackles (rales) and/or rhonchi; body temperature > 38°C or <36°C (before or during admission) or leucocytosis (> local ULN); new/increased pulmonary infiltrate(s) by chest imaging
- Need for non-invasive supplemental oxygen (NIAID-OS 5-6)
- SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300
- Females of child-bearing potential and with an active sexual life must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:; Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last IMP dose; A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last IMP dose; A male sexual partner who agrees to use a male condom with spermicide; A sterile sexual partner; Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, with child-bearing potential, pregnancy test result must be negative before first drug intake
Ki nem vehet részt
- Treatment with IMV or ECMO (NIAID-OS 7)
- Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
- Active bleeding or bleeding diathesis (excluding menses), prior intracranial haemorrhage
- Pregnancy:; positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
- Clinical condition not compatible with oral administration of the study drug
- Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
- Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score B or C)
- Renal dysfunction: estimated glomerular filtration rate (eGFR, MDRD) <50 mL/min/1.73 m2, or need for haemodialysis or hemofiltration
- Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anaemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
- History of:; intolerance or hypersensitivity to ibuprofen to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib (hypersensitivity to sulphanilamide antibiotics alone, e.g. sulfamethoxazole does not qualify for exclusion); lactase deficiency, galactosemia or glucose-galactose malabsorption; gastrointestinal bleeding or perforation due to previous NSAIDs therapy or recurrent peptic ulcer/haemorrhage; allergy to reparixin or any component of the IMP formulation
- Anticipated discharge from the hospital or transfer to another hospital within 72 hours of screening
- Participation in other interventional clinical trials
- Current hospital stay >72h
Helyszínek itt: Egyesült Államok
Még 6 másik országban, 46 helyszínen
- Emory Johns Creek HospitalAtlanta, Egyesült Államok
- Augusta University Health - Augusta University Medical CenterAugusta, Egyesült Államok
- Baptist Hospitals of Southeast TexasBeaumont, Egyesült Államok
- Beth Israel Deaconess Medical CenterBoston, Egyesült Államok
- NYU Langone Hospital - BrooklynBrooklyn, Egyesült Államok
- University of Virginia Medical CenterCharlottesville, Egyesült Államok
- Northwestern University Feinberg School of MedicineChicago, Egyesült Államok
- Research Alliance Inc.Clearwater, Egyesült Államok
- University Hospital - MU HealthcareColumbia, Egyesült Államok
- Texoma Medical CenterDenison, Egyesült Államok
- Denver HealthDenver, Egyesült Államok
- Duke University HospitalDurham, Egyesült Államok
- Methodist HospitalGary, Egyesült Államok
- University of Florida - JacksonvilleJacksonville, Egyesült Államok
- University of Tennessee Medical CenterKnoxville, Egyesült Államok
- MidMichigan Medical Center MidlandMidland, Egyesült Államok
- New York University Langone HealthNew York, Egyesült Államok
- Newton-Wellesley HospitalNewton, Egyesült Államok
- UCI HealthOrange, Egyesült Államok
- Jefferson University HospitalPhiladelphia, Egyesült Államok
- Oregon Health & Science University (OHSU) - Pulmonary ClinicPortland, Egyesült Államok
- Virginia Commonwealth University HealthRichmond, Egyesült Államok
- William Beaumont HospitalRoyal Oak, Egyesült Államok
- University of Utah Hospitals & ClinicsSalt Lake City, Egyesült Államok
- Mercy Research - St. LouisSt Louis, Egyesült Államok
- Washington University School of MedicineSt Louis, Egyesült Államok
- MD Banner University Medical Center /Arizona UniversityTucson, Egyesült Államok
- MedStar Health Research Institute-Hyatteville, MarylandWashington D.C., Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary objective:
A teljes eredeti leírásKevesebb
- To compare the efficacy of reparixin vs. placebo in the proportion of patients dead or requiring IMV (or ECMO) by Day 28.
Key secondary objectives:
* To compare the efficacy of reparixin vs placebo in all-cause mortality at day 180. * To compare the efficacy of reparixin vs placebo in proportion of patients alive and discharged at day 28 * To compare the efficacy of reparixin vs placebo in ventilatory-free days at day 28. * To compare the efficacy of reparixin vs placebo in proportion of patients with IMV (or ECMO) by day 28. * To compare the efficacy of reparixin vs placebo in length of primary hospital stay.
Other efficacy objectives
- To compare the efficacy of reparixin vs placebo on several disease severity/progression measures including recovery, ventilatory free days and mortality.
Safety objectives:
- To evaluate safety and tolerability of oral reparixin versus placebo in the specific clinical setting.
A vizsgálat 2 csoportja
- Reparixin + standard of care (SoC)A vizsgált kezelés
Reparixin was administered orally at the dose of 1200 mg (2 x 600 mg tablets) TID (6 tablets daily) for up to 21 days. The three daily doses were administered maintaining an interval between doses of about 8 hours.
Kezelés: Reparixin
- Placebo + standard of care (SoC)Placebo, összehasonlításként
Placebo tablets are identical in appearance to the active formulation. Placebo was administered with the same treatment schedule.
Kezelés: Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Reparixin 1200 mg TID as add-on to SoC to Limit Disease Progression in Hospitalised Patients With COVID-19 and Other Community-Acquired Pneumonia. A Multicentre, Randomized, Double-blinded, Placebo-controlled, Phase III Trial (REPAVID-22)
- A regiszteradat frissítve
- 2026. február 24.